

CERTIFIED TRUE COPY OF THE RESOLUTION PASSED IN THE MEETING OF THE IPO COMMITTEE OF THE BOARD OF DIRECTORS OF EMCURE PHARMACEUTICALS LIMITED HELD ON SATURDAY, DECEMBER 16, 2023.

APPROVAL OF THE DRAFT RED HERRING PROSPECTUS FOR THE INITIAL PUBLIC OFFER

“RESOLVED THAT, in furtherance of the resolution passed by the Board on December 11, 2023 authorizing the proposed Initial Public Offer and on December 15, 2023 approving the draft of the draft red herring prospectus (“DRHP”) and subject to and in accordance with all applicable laws including the Companies Act, 2013, and rules made thereunder, as amended, the Securities and Exchange Board of India Act, 1992, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”) and other regulations issued by Securities and Exchange Board of India (“SEBI”) in connection with the proposed Initial Public Offer consisting of a fresh issue of equity shares of Rs. 10 each of the Company (the “Equity Shares”) aggregating up to Rs. 8000 million (including share premium) (the “Fresh Issue”) and offer for sale by the existing shareholders (the “Offer”) at such price as may be determined in accordance with the book building process under the SEBI ICDR Regulations and as agreed to by the Company and the Selling Shareholders in consultation with the Book Running Lead Managers to the Offer, containing the requisite information as prescribed by applicable laws and regulations, and subject to the DRHP being duly signed by the Directors of the Company, the Chief Financial Officer of the Company and the Selling Shareholders (or their duly authorised representative), the DRHP dated December 16, 2023, as provided to and placed before the members of the IPO Committee be and is hereby approved for filing with the SEBI, the BSE Limited, the National Stock Exchange of India Limited (“Stock Exchanges”) where the Equity Shares are proposed to be listed and any other regulatory authority or persons as may be required or necessary.

RESOLVED FURTHER THAT any Director and Key Managerial Personnel of the Company, be and are hereby severally authorised to do all such acts, things and deeds on behalf of the Company to effectively implement this resolution.

RESOLVED FURTHER THAT any Director and Key Managerial Personnel of the Company, be and are hereby severally authorized to issue certified true copies of the resolution as may be required from time to time.”

// CERTIFIED TO BE TRUE//

FOR EMCURE PHARMACEUTICALS LIMITED



CHETAN SHARMA

COMPANY SECRETARY

MEMBERSHIP NO: F8352

ADDRESS: PLOT NO. P-1 & P-2,

IT-BT PARK, PHASE-II, M.I.D.C,

HINJAWADI, PUNE - 411057



Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: U24231PN1981PLC024251